Table 3.
Systemic treatment for 46 children with Behçet’s disease in a single UK paediatric rheumatology tertiary centre
| Total patients receiving treatment at any time (%) | First line systemic therapy no. (%) of patients | |
|---|---|---|
| Colchicine (0.5–2 mg/day) | 35 (76.1) | 24 (52.2) |
| Thalidomide | 13 (28.3) | 5 (10.9) |
| Oral prednisolone | 20 (45.5) | 8 (17.3) |
| Short coursea (0.5–1 mg/kg/day) | 6 (13.0) | 6 (13.0) |
| Continuousb (0.5–1 mg/kg/day) | 14 (30.4) | 2 (4.3) |
| Azathioprine | 15 (32.6) | 5 (10.9) |
| Sulfasalazine | 3 (6.5) | 1 (2.2) |
| Methotrexate | 3 (6.5) | 2 (4.3) |
| Adalimumab | 5 (10.9) | – |
| Infliximab | 1 (2.2) | – |
| Etanercept | 1 (2.2) | – |
aShort course oral prednisolone = a course of continuous oral prednisolone for <28 days
bContinuous oral prednisolone = continuous oral prednisolone >28 days